logo
ProjectSigned

EXEVIR (COVID-19) (IDFF)

The status, timeline and source of this project. A free account opens every field.

Source: European Investment Bank (EIB)

The promoter is a Belgium-based clinical stage company that develops single-domain antibody-based therapies (VHH or nanobodies).

The EIB loan will finance the promoter's research and development (R&D) activities to further develop the company's lead candidate, XVR012, a COVID-19 therapeutic product derived from llama-derived nanobodies.

Status
Under Construction
Sector
Government
Location
Belgium
Updated
22 Jul 2026
Source
European Investment Bank (EIB)

ConstructChat

Ask ConstructChat about EXEVIR (COVID-19) (IDFF)

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “EXEVIR (COVID-19) (IDFF)” is an infrastructure initiative in the Government sector, located in Belgium. Taiyo aggregates data on it from European Investment Bank (EIB).

Participants

Sponsoring Agency

Status

Original status

signed

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The promoter is a Belgium-based clinical stage company that develops single-domain antibody-based therapies (VHH or nanobodies). The EIB loan will finance the promoter's research and development (R&D) activities to further develop the company's lead candidate, XVR012, a COVID-19 therapeutic product derived from llama-derived nanobodies.

Original sector

Industry

Location

Country

Belgium

Source

Source

European Investment Bank (EIB)

URL

More Details

Record type

Project

Sector

Government

Article published date

2025-07-28

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project